Characteristic | Patients | Metastases |
Age (y) | ||
Mean ± SD | 64 ± 10.5 | |
Range | 43–91 | |
Sex | ||
Male | 24 | |
Female | 11 | |
Blood glucose | ||
Mean ± SD | 106 ± 15 | |
Range | 71–139 | |
C-reactive protein | ||
Mean ± SD | 0.2 ± 0.3 | |
Range | 0.0–2.3 | |
Carcinoembryonic antigen | ||
<5.0 | 29 | |
≥5.0 | 26 | |
Metastatic lesions | ||
Liver | 38 | |
Lung | 11 | |
Distant lymph nodes | 4 | |
Peritoneal dissemination | 2 | |
Timing | ||
Synchronous | 12 | |
Metachronous | 43 | |
No. of metastases/patient | ||
1 | 23 | |
2 | 8 | |
3 | 1 | |
4 | 2 | |
5 | 1 | |
Tumor size (mm) | ||
Mean ± SD | 20.9 ± 14.2 | |
Range | 7–81 | |
SUVmax | ||
Mean ± SD | 5.9 ± 3.6 | |
Range | 1.2–19.7 | |
KRAS status | ||
Mutated | 30 | |
Wild-type | 25 |